Recently published results of a GDNF intraputaminal infusion clinical trial Posted on March 5, 2019 by Phil Franchina A clinical trial, is by definition an experiment or a test — an effort to determine if something works,...see more or doesn’t. Sometimes, although the intended outcome of a clinical trial may fall short of expectations, the results are nevertheless intriguing and may spark additional avenues of investigation. Such is the case in a clinical trial […] Read More
FDA Approves Inbrija™ (levodopa inhalation powder) Parkinson’s disease Posted on December 23, 2018December 26, 2018 by Phil Franchina FDA Approves Inbrija™ (levodopa inhalation powder) December 22, 2018 Acorda Therapeutics announced the FDA approval of INBRIJA™ (levodopa inhalation powder)...see more for the treatment of OFF periods in people with Parkinson’s disease (PD) taking carbidopa/levodopa. INBRIJA™ is expected to be available by prescription in the first quarter of 2019, to be distributed through a network of specialty […] Read More
FDA Approves Focused Ultrasound for Tremor-predominant Parkinson’s disease Posted on December 20, 2018December 23, 2018 by Phil Franchina FDA approves focused ultrasound for tremor-predominant Parkinson’s disease December 19, 2018 Tremor-predominant Parkinson’s disease (PD) joins Essential tremor (ET)...see more as an FDA-approved indication for the use of Focused ultrasound. Focused ultrasound is a technology in which beams of ultrasound waves are focused on a designated target thereby concentrating enough energy to create a small lesion. […] Read More
Could Coffee Protect Neurons in Parkinson’s Disease? Posted on December 14, 2018February 19, 2019 by Phil Franchina Could coffee protect neurons in Parkinson’s disease? A recently published paper reveals interesting connections between coffee and Parkinson’s disease (PD). Read More
Vascular Parkinsonism in the News Posted on December 3, 2018March 29, 2019 by Phil Franchina George H.W. Bush, the 41st President of the United States died on November 30, 2018,...see more at the age of 94. Read More
The relationship between the appendix and Parkinson’s disease Posted on November 5, 2018April 3, 2019 by Phil Franchina Read More
Important New Study Underway: Get Involved Posted on October 23, 2018October 23, 2018 by Phil Franchina About the “Economic Burden” Study The study seeks to capture more of the financial costs associated with Parkinson’s. Read More
INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS® – Parkinson’s Disease Updates Posted on October 9, 2018April 2, 2019 by Phil Franchina INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS® - Parkinson's Disease Updates The International Congress of Parkinson’s Disease and Movement...see more Disorders is taking place this week (Oct 5-9) in Hong Kong. This is an annual meeting of Movement Disorders scientists and physicians from around the world. Read More
APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other conditions Posted on September 27, 2018September 27, 2018 by Phil Franchina APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other neuropsychiatric conditions In classic biochemistry,...see more ribonucleic acid (RNA) was thought to be a simple middle man between our genome and our proteins. Recently, however, it has become clear that RNA exists in multiple forms and plays a myriad of roles, including regulating protein production, regulating genome activity, and sensing environment. In fact, only a very small portion of DNA gets transcribed into RNA that creates protein. A much large portion gets transcribed into RNA that has various other functions. Read More
FDA New Analysis on PD Psychosis Treatment Posted on September 25, 2018September 27, 2018 by Phil Franchina On September 20, 2018, the FDA recently released results of a new analysis...see more finding no new or unexpected safety risks associated with Nuplazid. The new analysis was initiated because of concerns raised in the media last spring, and reassures patients that they should continue to take Nuplazid as prescribed by their physician. The FDA report highlights a number of important concepts Read More
